ClinicalTrials.gg
RecruitingNCT07367022PrSMUpdated Jan 26, 2026

Portable Sleep Monitors in Children With Autism Spectrum Disorder

An observational study in Autism Spectrum Disorder (ASD) and Obstructive Sleep Apnea (OSA), sponsored by Lena Xiao. Recruiting at 1 site in Canada. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Lena Xiao · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies in Autism Spectrum Disorder with a site in Canada — 15 open to participants now, 18 under way, 1 of them phase 3. Autism Spectrum Disorder · Canada.

Started
2025
with 3 others
Observational
7 of 70
3 open now
Primary completion
2026-12
later than 6 of 17 live
Registered
67th of 70
by date

Among the 70 studies in Autism Spectrum Disorder with a site in Canada, this one is one of 4 that started in 2025, is one of 7 observational ones, reaches primary completion later than 6 of the 17 other live ones, and was the 67th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

15 of the 70 studies in Autism Spectrum Disorder with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Autism Spectrum Disorder with a site in Canada, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the ability of a portable sleep monitor to detect obstructive sleep apnea in children with autism spectrum disorder (ASD). The main study objectives are to:

  1. Evaluate the correlation between the obstructive apnea-hypopnea index (OAHI) on a portable sleep monitor and an in-laboratory polysomnogram (PSG);
  2. Determine the sensitivity and specificity of a portable sleep monitor to diagnose obstructive sleep apnea (OSA);
  3. Evaluate patient and family preferences for sleep testing.
Read the detailed description

Sleep disorders are highly prevalent in children with ASD, with as many as 80% of children reporting poor sleep. To identify the cause of poor sleep, many children will require a sleep study (polysomnogram; PSG), which is an overnight study done at the hospital using many different sensors to measure sleep and breathing. The PSG is the gold standard diagnostic test for obstructive sleep apnea (OSA) and measures the rate of obstructive respiratory events during sleep (obstructive apnea-hypopnea index; OAHI) which is crucial for treatment decision-making. However, PSGs are challenging for children with ASD due to the disrupted routine, burden and stress, and intolerance to the PSG setup. Further, diagnosis may be delayed up to 2 years due to a lack of pediatric sleep facilities in Canada, with pronounced geographical disparities. Although sleep disturbances are prevalent amongst children with ASD, there are significant inequities in accessing pediatric sleep medicine care and diagnostic testing. Alternative, simpler diagnostic testing is needed.

We will evaluate a portable sleep monitor as the first step towards establishing home sleep apnea testing in children with ASD. We will conduct a feasibility study testing the Nox T3s portable sleep monitor alongside the traditional in-hospital polysomnogram to compare the ability of the Nox T3s to identify obstructive sleep apnea in children with ASD. We will also conduct qualitative interviews with families to gather insight on participant and family preferences for sleep testing to better address the needs of children with ASD.

03

Conditions studied

  • Autism Spectrum Disorder (ASD)
  • Obstructive Sleep Apnea (OSA)

Keywords

  • Portable Sleep Monitor
  • Polysomnogram
  • Children with ASD
  • Nox T3s
  • Sleep Disordered Breathing
  • Sleep disorder
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children who are undergoing a clinical PSG at British Columbia's Children's Hospital in Vancouver, Canada.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children between 6 to 18 years of age, AND;
  2. Children diagnosed with autism spectrum disorder, AND;
  3. Children who will be undergoing a polysomnogram (PSG) for the first time, AND;
  4. Caregiver willing to complete questionnaires about child's sleep and behavior

Exclusion criteria

Exclusion Criteria:

  1. Children who are currently using respiratory therapy
  2. Children who have previously completed a PSG
  3. Caregiver unwilling to complete questionnaires about child's sleep and behavior
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children with ASD testing a portable sleep monitor

    Children aged 6-18 years old with autism spectrum disorder concurrently testing a portable sleep monitor (Nox T3s) during their first clinical polysomnogram. Children and their caregivers may also complete a qualitative interview about sleep testing preferences after their sleep test.

    Device: Portable sleep monitor (Nox T3s)

Interventions

  • DevicePortable sleep monitor (Nox T3s)

    Participants will test the Nox T3s portable sleep monitor concurrently during their in-hospital clinical polysomnogram.

06

What researchers measure

Primary outcomes

  1. Obstructive Apnea-Hypopnea Index (OAHI) measured from the portable sleep monitor and from the polysomnogram (PSG)

    The OAHI measured from the portable sleep monitor will be compared to the OAHI measured from the PSG, the gold standard test for sleep-disordered breathing, to determine the ability of the portable sleep monitor to diagnose obstructive sleep apnea.

    Time frame: Baseline

Secondary outcomes

  1. Patient and Family Preferences

    Optional semi-structured qualitative interviews with caregivers and the patient, if they choose to and are capable of participating in the interviews. The interviews will be conducted virtually by a study team member to explore patient and family preferences and experiences with diagnostic sleep testing.

    Time frame: 0-3 months after the baseline PSG

  2. Insomnia Questionnaire

    The caregiver-reported Pediatric Insomnia Severity Index will be used to measure the severity of pediatric insomnia symptoms. Scores range from 0 to 30, with higher scores indicating greater insomnia severity.

    Time frame: +/- 1 week from baseline PSG sleep test

  3. Chronotype Questionnaire

    The caregiver-reported Children's Chronotype Questionnaire will measure the chronotype of the participant. The caregiver is given a short description of different chronotypes and selects the chronotype that best reflects their child's preference from a 5-point scale, ranging from "Definitely a Morning Type" = 1 to "Definitely an Evening Type" = 5.

    Time frame: +/- 1 week from baseline PSG sleep test

  4. Chronotype Questionnaire

    The Morningness/Eveningness Scale from the caregiver-reported Children's Chronotype Questionnaire will measure the participant's differences in activeness and alertness in the mornings and evenings. Scores range from 10-48, with scores indicating a morning type (≤ 23), intermediate type (24-32), and evening type (≥33).

    Time frame: +/- 1 week from baseline PSG sleep test

  5. Chronotype Questionnaire

    The sleep and wake parameters from the caregiver-reported Children's Chronotype Questionnaire will measure the participant's midsleep point on free days (MSF).

    Time frame: +/- 1 week from baseline PSG sleep test

  6. Sleep Questionnaire

    The caregiver-reported Pediatric Sleep Questionnaire: Sleep-Related Breathing Disorders subscale will measure the risk for sleep-related breathing disorders. The questionnaire contains 22-items scored as "yes" = 1 and "no" = 0 and normalized to the total number of questions answered, yielding a score between 0.0-1.0. Scores \>0.33 indicate a high risk for sleep-related breathing disorders.

    Time frame: +/- 1 week from baseline PSG sleep test

  7. Psychological Scale (Emotional Symptoms)

    The Emotional Symptoms subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating greater emotional difficulties.

    Time frame: +/- 1 week from baseline PSG sleep test

  8. Psychological Scale (Conduct Problems)

    The Conduct Problems subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating greater conduct difficulties.

    Time frame: +/- 1 week from baseline PSG sleep test

  9. Psychological Scale (Hyperactivity/inattention)

    The Hyperactivity/inattention subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating greater hyperactivity/inattention problems.

    Time frame: +/- 1 week from baseline PSG sleep test

  10. Psychological Scale (Peer Relationship Problems)

    The Peer Relationship Problems subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating greater peer relationship problems.

    Time frame: +/- 1 week from baseline PSG sleep test

  11. Psychological Scale (Pro-Social)

    The Pro-Social subscale of the Strengths and Difficulties Questionnaire will be used. The 5-item subscale score ranges from 0-10, with greater scores indicating less difficulty and an increased aptitude for kind and helpful behaviour.

    Time frame: +/- 1 week from baseline PSG sleep test

  12. Psychological Scale (Total Difficulties)

    The Total Difficulties/Overall Stress scale of the Strengths and Difficulties Questionnaire will be calculated by totaling the following 4 subscales: emotional, conduct, hyperactivity, and peer relationships. The total score ranges from 0-40, with greater scores indicating greater difficulties and overall stress.

    Time frame: +/- 1 week from baseline PSG sleep test

  13. Sensory Scale (Auditory Hypersensitivity)

    The Auditory Hypersensitivity subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 9-36, with greater scores indicating higher sensitivity for, and problems with, sounds related to auditory danger signals.

    Time frame: +/- 1 week from baseline PSG sleep test

  14. Sensory Scale (Auditory Hyposensitivity to Voices)

    The Auditory Hyposensitivity to Voices subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 5-20, with greater scores indicating reduced sensitivity for speech or voices.

    Time frame: +/- 1 week from baseline PSG sleep test

  15. Sensory Scale (Visual Hypersensitivity)

    The Visual Hypersensitivity subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 10-40, with greater scores indicating increased sensitivity to light and movement.

    Time frame: +/- 1 week from baseline PSG sleep test

  16. Sensory Scale (Tactile Hypersensitivity)

    The Tactile Hypersensitivity subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 10-40, with greater scores indicating increased sensitivity to non-social touch.

    Time frame: +/- 1 week from baseline PSG sleep test

  17. Sensory Scale (Affiliative Touch Aversion)

    The Affiliative Touch Aversion subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 3-12, with greater scores indicating increased negative response to social touch.

    Time frame: +/- 1 week from baseline PSG sleep test

  18. Sensory Scale (Selective Eating)

    The Selective Eating subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 6-24, with greater scores indicating increased selectivity in food choices (i.e. picky eating).

    Time frame: +/- 1 week from baseline PSG sleep test

  19. Sensory Scale (Ingestive Problems)

    The Ingestive Problems subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 3-12, with greater scores indicating increased problems with swallowing and retaining food.

    Time frame: +/- 1 week from baseline PSG sleep test

  20. Sensory Scale (Digestive Problems)

    The Digestive Problems subscale of the Body Brain Center Sensory Scales will be used. The subscale score ranges from 4-16, with greater scores indicating increased problems with digestion.

    Time frame: +/- 1 week from baseline PSG sleep test

  21. Autism Symptoms Dimensions Scale

    The caregiver-reported Autism Symptoms Dimensions Scale (ASDS) will be used to measure core autism symptoms in children and adolescents. The 39-item questionnaire is scored on a 5-point scale with total ASDS scores ranging from 39-195. Scores between 114-130 indicate high symptom levels and scores \>130 indicate very high symptom levels.

    Time frame: +/- 1 week from baseline PSG sleep test

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 16 months is below that.

Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Jan 26, 2026
StartActual
Aug 12, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07367022
Lead sponsor
Lena Xiao
Responsible party
Lena Xiao (Clinical Assistant Professor, University of British Columbia) — Sponsor-investigator
First posted
Jan 26, 2026
Start date
Aug 12, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Lena J Xiao, MD MSc
Contact
lena.xiao@cw.bc.ca
604-875-2345 ext. 7606
Macyn LY Leung, MSc
Contact
macyn.leung@bcchr.ca
604-875-2345 ext. 7606

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion